	US 11,685,777 B2
	Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof
Ricardo Attar, Lawrenceville, NJ (US); Francois Gaudet, Spring House, PA (US); Mark Tornetta, Collegeville, PA (US); Alexey Teplyakov, Phoenixville, PA (US); Mark Mendonca, Philadelphia, PA (US); Suzanne Edavettal, San Diego, CA (US); Kodandaram Pillarisetti, Spring House, PA (US); Nathan Majewski, Warrington, PA (US); Yingzhe Li, Dresher, PA (US); Leopoldo L. Luistro, III, Lansdale, PA (US); and Diana Chin, Norwood, PA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Feb. 3, 2020, as Appl. No. 16/779,713.
Application 16/779,713 is a division of application No. 15/655,086, filed on Jul. 20, 2017, granted, now 10,562,968.
Claims priority of provisional application 62/364,811, filed on Jul. 20, 2016.
Prior Publication US 2023/0084967 A1, Mar. 16, 2023
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/28 (2013.01) [A61K 39/0011 (2013.01); C07K 16/2809 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

9 Claims

1. An isolated GPRC5D x CD3 bispecific antibody comprising:

a) a first heavy chain (HC1);

b) a second heavy chain (HC2);

c) a first light chain (LC 1); and

d) a second light chain (LC2),

wherein the HC1 and the LC1 pair to form a first antigen-binding site that specifically binds CD3, and the HC2 and the LC2 pair to form a second antigen-binding site that specifically binds GPRC5D;

wherein the HC1 comprises the amino acid sequence of SEQ ID NO: 25 and the LC1 comprises the amino acid sequence of SEQ ID NO: 26, and

wherein the HC2 comprises the amino acid sequence of SEQ ID NO: 55 and the LC2 comprises the amino acid sequence of SEQ ID NO: 58.